ERR2208908
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.700
- INFLAMMATORY_RESPONSE+0.700
- INTERFERON_ALPHA_RESPONSE+0.700
- INTERFERON_GAMMA_RESPONSE+0.700
- ALLOGRAFT_REJECTION+0.600
- ANGIOGENESIS+0.600
- COMPLEMENT+0.600
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.600
- TNFA_SIGNALING_VIA_NFKB+0.600
- COAGULATION+0.500
Top 10 suppressed
- MYC_TARGETS_V2-0.500
- DNA_REPAIR-0.300
- HEDGEHOG_SIGNALING-0.200
- MYC_TARGETS_V1-0.200
- WNT_BETA_CATENIN_SIGNALING-0.200
- MITOTIC_SPINDLE-0.100
- SPERMATOGENESIS-0.100
- BILE_ACID_METABOLISM+0.000
- E2F_TARGETS+0.000
- NOTCH_SIGNALING+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2651 | Med | Medulloblastoma | 0.921 |
| 2 | s_150324_4b | EPN | Posterior Fossa EPN | 0.920 |
| 3 | EPT0509 | EPN | EPN Tumor | 0.918 |
| 4 | TCGA-75-5126-01A-01R-1755-07 | — | cohortA1 | 0.908 |
| 5 | AUR-AFEC-TTM6-A-1-1-R-A742-41 | — | C | 0.907 |
| 6 | s0122206 | — | — | 0.906 |
| 7 | MDT-AP-0355 | Med | Medulloblastoma | 0.906 |
| 8 | BS_HJRTC9JQ | high-grade glioma | — | 0.905 |
| 9 | SRR10900576 | — | — | 0.902 |
| 10 | 24d909f2-cdc8-4509-91d5-e18fffcf90eb | — | — | 0.902 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.700 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.700 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.700 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.700 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.600 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.600 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.600 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.600 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.600 | Inavolisib | — uncovered |
| COAGULATION | 0.500 | Binimetinib | — uncovered |
| HYPOXIA | 0.500 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.500 | Inavolisib | — uncovered |
| APOPTOSIS | 0.400 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.400 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.400 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |